Cargando…

Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCS...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianconi, Vanessa, Cafaro, Giacomo, Mannarino, Massimo Raffaele, Perricone, Carlo, Cosentini, Elena, Bistoni, Onelia, Paltriccia, Rita, Lombardini, Rita, Gerli, Roberto, Pirro, Matteo, Bartoloni, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527459/
https://www.ncbi.nlm.nih.gov/pubmed/37759784
http://dx.doi.org/10.3390/biom13091384
_version_ 1785111152831758336
author Bianconi, Vanessa
Cafaro, Giacomo
Mannarino, Massimo Raffaele
Perricone, Carlo
Cosentini, Elena
Bistoni, Onelia
Paltriccia, Rita
Lombardini, Rita
Gerli, Roberto
Pirro, Matteo
Bartoloni, Elena
author_facet Bianconi, Vanessa
Cafaro, Giacomo
Mannarino, Massimo Raffaele
Perricone, Carlo
Cosentini, Elena
Bistoni, Onelia
Paltriccia, Rita
Lombardini, Rita
Gerli, Roberto
Pirro, Matteo
Bartoloni, Elena
author_sort Bianconi, Vanessa
collection PubMed
description Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCSK9, measures of immune–inflammatory status and markers of atherosclerosis in 52 consecutive patients with primary Sjögren’s syndrome (pSS) in comparison to healthy controls (HCs). Median plasma PCSK9 levels were significantly higher in pSS patients versus HCs (162 (79–255) vs. 53 (39–99) ng/mL). Significantly higher prevalence of subclinical atherosclerosis and lower of dyslipidaemia (61% vs. 85%, p = 0.042) characterized pSS patients versus HCs. In pSS, no significant correlation emerged between PCSK9 and disease activity, atherosclerosis and lipid levels. In HCs, PCSK9 significantly correlated with lipid levels and atherosclerosis. Interestingly, significantly higher PCSK9 levels were found in HCs with high-to-very-high as compared to low-to-moderate CV risk (p = 0.018) while a non-significant trend towards higher PCSK9 levels was detected in pSS patients with low-to-moderate as compared to high-to-very-high CV risk (p = 0.060). This is the first demonstration that pSS patients, despite lower prevalence of dyslipidaemia and higher CV risk profile, are characterized by a 3-fold increase in PCSK9 levels in comparison to HCs. As PCSK9 does not correlate with measures of CV risk, its role in CV morbidity in pSS needs further investigation.
format Online
Article
Text
id pubmed-10527459
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105274592023-09-28 Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome Bianconi, Vanessa Cafaro, Giacomo Mannarino, Massimo Raffaele Perricone, Carlo Cosentini, Elena Bistoni, Onelia Paltriccia, Rita Lombardini, Rita Gerli, Roberto Pirro, Matteo Bartoloni, Elena Biomolecules Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCSK9, measures of immune–inflammatory status and markers of atherosclerosis in 52 consecutive patients with primary Sjögren’s syndrome (pSS) in comparison to healthy controls (HCs). Median plasma PCSK9 levels were significantly higher in pSS patients versus HCs (162 (79–255) vs. 53 (39–99) ng/mL). Significantly higher prevalence of subclinical atherosclerosis and lower of dyslipidaemia (61% vs. 85%, p = 0.042) characterized pSS patients versus HCs. In pSS, no significant correlation emerged between PCSK9 and disease activity, atherosclerosis and lipid levels. In HCs, PCSK9 significantly correlated with lipid levels and atherosclerosis. Interestingly, significantly higher PCSK9 levels were found in HCs with high-to-very-high as compared to low-to-moderate CV risk (p = 0.018) while a non-significant trend towards higher PCSK9 levels was detected in pSS patients with low-to-moderate as compared to high-to-very-high CV risk (p = 0.060). This is the first demonstration that pSS patients, despite lower prevalence of dyslipidaemia and higher CV risk profile, are characterized by a 3-fold increase in PCSK9 levels in comparison to HCs. As PCSK9 does not correlate with measures of CV risk, its role in CV morbidity in pSS needs further investigation. MDPI 2023-09-12 /pmc/articles/PMC10527459/ /pubmed/37759784 http://dx.doi.org/10.3390/biom13091384 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bianconi, Vanessa
Cafaro, Giacomo
Mannarino, Massimo Raffaele
Perricone, Carlo
Cosentini, Elena
Bistoni, Onelia
Paltriccia, Rita
Lombardini, Rita
Gerli, Roberto
Pirro, Matteo
Bartoloni, Elena
Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
title Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
title_full Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
title_fullStr Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
title_full_unstemmed Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
title_short Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
title_sort exploring the link between plasma levels of pcsk9, immune dysregulation and atherosclerosis in patients with primary sjögren’s syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527459/
https://www.ncbi.nlm.nih.gov/pubmed/37759784
http://dx.doi.org/10.3390/biom13091384
work_keys_str_mv AT bianconivanessa exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT cafarogiacomo exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT mannarinomassimoraffaele exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT perriconecarlo exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT cosentinielena exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT bistonionelia exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT paltricciarita exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT lombardinirita exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT gerliroberto exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT pirromatteo exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome
AT bartolonielena exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome